# Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma

> **NCT00784290** · PHASE1,PHASE2 · COMPLETED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 35 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Orantinib (TSU-68)

## Key facts

- **NCT ID:** NCT00784290
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2010-10
- **Final completion:** 2012-03
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2012-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00784290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00784290, "Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00784290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*